Locations:
Search IconSearch
March 2, 2018/Cancer/News & Insight

Waiting to Treat the Cancer

When insurance delays mean poorer prognosis

650×450-Cleveland-Clinic-Cancer

Mikkael Sekeres, MD, MS, shares a story illustrating that even when patients, doctors and health systems emphasize time to treat, insurance processes can delay treatment. He writes:

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“But I wondered whether the delays in his treatment hadn’t worsened his chance of being cured. I understand that, particularly in this age of breathtakingly expensive cancer treatment, there is a need for checks and balances on our treatment recommendations and their potential benefit. That public health perspective seemed awfully shortsighted, though, when I had to face my patient and his dad each week as his leukemia threatened to come raging back.”

Read the entire New York Times column.

Dr. Sekeres is Director of Cleveland Clinic Cancer Center’s Leukemia Program.

Advertisement

Related Articles

adverse events from immune checkpoint inhibitors
December 21, 2023/Cancer/News & Insight
Managing Hormone Dysfunction-Related Adverse Events of Immunotherapy for Breast Cancer Treatment

Timing and type of side effects differ greatly from chemotherapy

23-CNR-4274330-CQD-Hero-650×450
October 18, 2023/Cancer/News & Insight
Cleveland Clinic Lerner Research Institute to Host Head & Neck Cancer CME Symposium

Sessions explore treatment advances and multidisciplinary care

23-CNR-4210971-CQD-Hero-650×450 Dr Yu
October 9, 2023/Cancer/News & Insight
Pathway Cross-Talk Suggests New Approach to Glioblastoma Treatment

New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues

23-CNR-4071967-CQD-Hero-650×450 scan for triple-negative breast cancer case study
September 19, 2023/Cancer/News & Insight
Patient With Stage 4 Triple-Negative Breast Cancer in Remission 10 Years After Initial Diagnosis

Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations

23-CNR-4140381-CQD-Hero-650×450 eye toxicities in cancer treatment
September 7, 2023/Cancer/News & Insight
Eye Toxicities More Prevalent Side Effect of Cancer Treatment Than Previously Understood

Early communication between oncologists and ophthalmologist warranted

23-CNR-4185077-CQD-Hero-650×450
August 31, 2023/Cancer/News & Insight
CME Program Takes Multidisciplinary Approach to Colorectal Cancer

Case-based course delves into latest treatment approaches

outreach to underserved communities
June 2, 2023/Cancer/News & Insight
Focus Groups Amplify the Voices of Black Congregants about Disparities in Clinical Trials

Long-term relationship building and engagement key to gaining community trust

Ad